• Ning Li, Qiu-Mei Yao, Robert Peter Gale, Jin-Lan Li, Ling-Di Li, Xiao-Su Zhao, Hao Jiang, Qian Jiang, Bin Jiang, Hong-Xia Shi, Shan-Shan Chen, Kai-Yan Liu, Xiao-Jun Huang, and Guo-Rui Ruan.
• Peking University People's Hospital and Institute of Hematology, 11 Xi-Zhi-Men South Street, Beijing 100044, China.
• Leuk. Res. 2015 May 1; 39 (5): 510-4.

AbstractCALR mutations are detected in about 50% of persons of predominately European descent with essential thrombocythemia (ET) or primary myelofibrosis (PMF) with wild-type alleles of JAK2 and MPL. We studied 1088 Chinese with diverse myeloproliferative neoplasms including ET (N=234) and PMF (N=50) without JAK2(V617F) or MPL exon 10 mutations. CALR mutation was detected in 53% (95% CI, 46-60%) of subjects with ET and 56% (95% CI, 41-70%) of subjects with PMF. 152 CALR mutations were identified clustering into 15 types including deletions (N=8), insertions (N=3) and complex indels (N=4). We also identified 9 new mutations. Mean (±SD) mutant allele burden was 31±12% (range, 0.5-69%). Persons with PMF had higher CALR mutant allele burdens than those with ET (38±8% vs. 29±12%; P<0.001). Amongst persons with CALR mutations, those with PMF had different clinical features from those with ET. These data may be useful for diagnosing ET and PMF in Chinese who are about 40% of all persons with ET and PMF and for monitoring therapy-response. They also highlight similarities and differences in CALR mutations between Chinese and persons of predominately European descent with these diseases. Copyright © 2015 Elsevier Ltd. All rights reserved.

36 keywords...

hide…